Dr Scott Morris, MD | |
1150 Main St Ste 10, Concord, MA 01742-3058 | |
(617) 734-1540 | |
(617) 505-1809 |
Full Name | Dr Scott Morris |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 18 Years |
Location | 1150 Main St Ste 10, Concord, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356461156 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 240368 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Scott Morris, MD 1150 Main St Ste 10, Concord, MA 01742-3058 Ph: (617) 734-1540 | Dr Scott Morris, MD 1150 Main St Ste 10, Concord, MA 01742-3058 Ph: (617) 734-1540 |
News Archive
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed an expanded contract manufacturing agreement with Merck & Co., Inc. (known as MSD outside of the U.S.A. and Canada).
An international research collaboration led by UCL scientists has developed ways to improve the quality and accuracy of information harvested from epigenome sequencing datasets in two new research papers published jointly in Nature Biotechnology and Nature Communications today. According to the studies, epigenome sequencing technologies can allow for more comprehensive analysis of cancers - a key component in the development of targeted approaches to combat cancer.
OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
› Verified 3 days ago
Dr. Jeffrey Brian Hainsworth, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 131 Old Road To 9 Acre Cor Ste 430, Concord, MA 01742 Phone: 978-287-7481 Fax: 978-287-8983 | |
Aaron L. Frenz, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 330 Baker Ave, Concord, MA 01742 Phone: 978-287-9380 | |
Dr. Barbara P. Wissner, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 747 Main St, Suite 204, Concord, MA 01742 Phone: 978-371-2098 Fax: 978-371-2098 | |
Dr. Jennifer M Park, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 131 Old Road To 9 Acre Cor Ste 620, Concord, MA 01742 Phone: 703-403-4204 Fax: 571-446-4015 | |
Robert Parker Hopkins, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1266 Main St, Concord, MA 01742 Phone: 978-369-5454 Fax: 978-369-5454 | |
Dr. Stuart Wachter, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: John Cuming Bldg, 131 Ornac, Suite 580, Concord, MA 01742 Phone: 978-371-9690 Fax: 978-371-9691 | |
Lloyd Franklin Price, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 152 Holdenwood Rd, Concord, MA 01742 Phone: 978-369-1869 Fax: 978-371-2593 |